Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 70934-306 by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
70934 306 30 Master Bottle Label Approval Rev A 03 19
NDC: 70934-306-30 is a prescription drug. Its name is zZosin Hydrochloride and it is an extended-release tablet of 10mg strength, with a total count of 30 tablets. The manufacturer's name is not available from the text obtained by .*
chemical-structure - chemical structure
figure-1 - figure 1
figure-2 - figure 2
figure-3 - figure 3
This is a figure presenting the mean change from baseline in IPSS Total Symptom Score after 28 and 56 days of treatment with either placebo (N=152) or alfuzosin hydrochloride extended-release tablets (N=137), in Trial 2. The statistical significance is reported as **p < 0.01.*
figure-4 - figure 4
The given text depicts the analysis of trial 3, showcasing the comparison between A Placebo (N=150) and Aituzosin hydrochloride extended-release tablets (N=151) on the basis of their mean change from Baseline in IPSS Total Symptom Score. It is mentioned that the treatment lasted for 28 to 56 days, and the results indicate a significant improvement with Aituzosin hydrochloride extended-release tablets. Therefore, this text provides essential information on the efficacy of the drug in managing symptoms.*
figure-5 - figure 5
This is a graph that shows the mean change from baseline in peak urine flow rate in a clinical trial. There are two groups represented: a placebo group and a group taking alfuzosin hydrochloride extended-release tablets. The graph shows a significant improvement in the peak urine flow rate in the group taking alfuzosin hydrochloride compared to the placebo group. The X-axis represents the days of treatment and the Y-axis represents the change in urine flow rate in mL/s.*
figure-6 - figure 6
The given text appears to be from a scientific report or a research paper that includes a graph. The graph shows the mean change from baseline in peak urine flow rate over the course of 84 days of treatment for two groups: Placebo (N=147) and Atuzosin hydrochloride extended-release tablets (N=136). The x-axis represents the treatment duration in days, and the y-axis represents the peak urine flow rate in mL/s. The figure suggests that the Atuzosin group had a higher mean change in peak urine flow rate than the Placebo group. The asterisk (*) next to the x-axis label probably indicates statistical significance.*
figure-7 - figure 7
The text appears to be a graphical representation of a clinical trial comparing the effects of Placebo and Alfuzosin hydrochloride extended-release tablets on Peak Urine Flow Rate, with N=150 and N=151 respectively. The x-axis shows the number of days of treatment (14, 28, 56, and 84) and the y-axis depicts the Mean Change from Baseline in Peak Urine Flow Rate (in mL/s). The graph shows no statistically significant difference between the two treatments (NS p >0.05).*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.